Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7779)
All Articles published online
|
Publishing Process of This Article
|
Oct 21, 2014 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yao J, Zhou CS, Ma X, Fu BQ, Tao LS, Chen M, Xu YP. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol 2014; 20(39): 14430-14441 [PMID: 25339829 DOI: 10.3748/wjg.v20.i39.14430] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i39/14430.htm |
| Number | Citing Articles |
| 1 |
Mengjiao Zhou, Danfeng Wang, Xiang Li, Ying Cao, Chengxue Yi, Dickson Kofi Wiredu Ocansey, Yuling Zhou, Fei Mao. Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1016836
|
| 2 |
Sun-Gi Kim, Byung-Kwon Kim, Kyumin Kim, Sungsoon Fang. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism 2016; 31(4): 500 doi: 10.3803/EnM.2016.31.4.500
|
| 3 |
Ting Zhang, Qi Zhao, Xuerong Xiao, Rui Yang, Dandan Hu, Xu Zhu, Frank J. Gonzalez, Fei Li. Modulation of Lipid Metabolism by Celastrol. Journal of Proteome Research 2019; 18(3): 1133 doi: 10.1021/acs.jproteome.8b00797
|
| 4 |
Jaclynn A. Meshanni, Jordan M. Lee, Kinal N. Vayas, Rachel Sun, Chenghui Jiang, Grace L. Guo, Andrew J. Gow, Jeffrey D. Laskin, Debra L. Laskin. Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid. Journal of Pharmacology and Experimental Therapeutics 2024; 388(2): 586 doi: 10.1124/jpet.123.001557
|
| 5 |
Chang Yeob Han, Tae Hyun Kim, Ja Hyun Koo, Sang Geon Kim. Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. Archives of Pharmacal Research 2016; 39(8): 1062 doi: 10.1007/s12272-016-0812-y
|
| 6 |
Haiming Hu, Aizhen Lin, Mingwang Kong, Xiaowei Yao, Mingzhu Yin, Hui Xia, Jun Ma, Hongtao Liu. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. Journal of Gastroenterology 2020; 55(2): 142 doi: 10.1007/s00535-019-01649-8
|
| 7 |
Konstantin Kazankov, Simon Mark Dahl Jørgensen, Karen Louise Thomsen, Holger Jon Møller, Hendrik Vilstrup, Jacob George, Detlef Schuppan, Henning Grønbæk. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology 2019; 16(3): 145 doi: 10.1038/s41575-018-0082-x
|
| 8 |
Nikolaos Nikolaou, Laura L. Gathercole, Lea Marchand, Sara Althari, Niall J. Dempster, Charlotte J. Green, Martijn van de Bunt, Catriona McNeil, Anastasia Arvaniti, Beverly A. Hughes, Bruno Sgromo, Richard S. Gillies, Hanns-Ulrich Marschall, Trevor M. Penning, John Ryan, Wiebke Arlt, Leanne Hodson, Jeremy W. Tomlinson. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism 2019; 99: 67 doi: 10.1016/j.metabol.2019.153947
|
| 9 |
Carmelo Luci, Manon Bourinet, Pierre S. Leclère, Rodolphe Anty, Philippe Gual. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.597648
|
| 10 |
Shuni Duan, Xiaojiaoyang Li, Guifang Fan, Runping Liu. Targeting bile acid signaling for the treatment of liver diseases: From bench to bed. Biomedicine & Pharmacotherapy 2022; 152: 113154 doi: 10.1016/j.biopha.2022.113154
|
| 11 |
Yaron Ilan. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016; 310(11): G1102 doi: 10.1152/ajpgi.00095.2016
|
| 12 |
Da-Gang Zhang, Cheng Zhang, Jun-Xian Wang, Bi-Wei Wang, Hua Wang, Zhi-Hui Zhang, Yuan-Hua Chen, Yan Lu, Li Tao, Jian-Qing Wang, Xi Chen, De-Xiang Xu. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation. Toxicology and Applied Pharmacology 2017; 314: 39 doi: 10.1016/j.taap.2016.11.006
|
| 13 |
Kenneth C. P. Cheung, Jiao Ma, Rodrigo Azevedo Loiola, Xingxuan Chen, Wei Jia. Bile acid‐activated receptors in innate and adaptive immunity: targeted drugs and biological agents. European Journal of Immunology 2023; 53(8) doi: 10.1002/eji.202250299
|
| 14 |
Liangpeng Li, Qian Zhang, Jiahe Peng, Chanjui Jiang, Yan Zhang, Lili Shen, Jinyu Dong, Yongchao Wang, Yu Jiang. Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage. Biochemical and Biophysical Research Communications 2015; 467(4): 841 doi: 10.1016/j.bbrc.2015.10.056
|
| 15 |
Wenxuan Xu, Chunfeng Lu, Lu Yao, Feng Zhang, Jiangjuan Shao, Shizhong Zheng. Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner. Toxicology and Applied Pharmacology 2017; 315: 23 doi: 10.1016/j.taap.2016.12.001
|
| 16 |
Jeanne A. Ishimwe, Thanvi Dola, Lale A. Ertuglu, Annet Kirabo. Bile acids and salt-sensitive hypertension: a role of the gut-liver axis. American Journal of Physiology-Heart and Circulatory Physiology 2022; 322(4): H636 doi: 10.1152/ajpheart.00027.2022
|
| 17 |
Ye-Jee Lee, Esder Lee, Young-Hye You, Yu-Bae Ahn, Ki-Ho Song, Ji-Won Kim, Seung-Hyun Ko. Role of sirtuin-1 (SIRT1) in hypoxic injury in pancreatic β-cells. Journal of Drug Targeting 2021; 29(1): 88 doi: 10.1080/1061186X.2020.1806285
|
| 18 |
Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. European Journal of Medicinal Chemistry 2020; 197: 112311 doi: 10.1016/j.ejmech.2020.112311
|
| 19 |
Alexandra Zisser, David H. Ipsen, Pernille Tveden-Nyborg. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets?. Biomedicines 2021; 9(4): 365 doi: 10.3390/biomedicines9040365
|
| 20 |
Salisa Benjaskulluecha, Atsadang Boonmee, MdFazlul Haque, Benjawan Wongprom, Thitiporn Pattarakankul, Chitsuda Pongma, Kittitach Sri-ngern-ngam, Pornlapat Keawvilai, Thadaphong Sukdee, Benjawan Saechue, Patipark Kueanjinda, Tanapat Palaga. O6-methylguanine DNA methyltransferase regulates β-glucan-induced trained immunity of macrophages via farnesoid X receptor and AMPK. iScience 2024; 27(1): 108733 doi: 10.1016/j.isci.2023.108733
|
| 21 |
Wenhui Zhang, Ren Lang. Macrophage metabolism in nonalcoholic fatty liver disease. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1257596
|
| 22 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019; 84(1): 69 doi: 10.1016/j.rgmxen.2019.02.003
|
| 23 |
Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, Henning Grønbæk. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. Expert Review of Gastroenterology & Hepatology 2021; 15(1): 51 doi: 10.1080/17474124.2020.1817740
|
| 24 |
Leke Wiering, Frank Tacke. Treating inflammation to combat non-alcoholic fatty liver disease. Journal of Endocrinology 2023; 256(1) doi: 10.1530/JOE-22-0194
|
| 25 |
Runbin Sun, Na Yang, Bo Kong, Bei Cao, Dong Feng, Xiaoyi Yu, Chun Ge, Jingqiu Huang, Jianliang Shen, Pei Wang, Siqi Feng, Fei Fei, Jiahua Guo, Jun He, Nan Aa, Qiang Chen, Yang Pan, Justin D. Schumacher, Chung S. Yang, Grace L. Guo, Jiye Aa, Guangji Wang. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Molecular Pharmacology 2017; 91(2): 110 doi: 10.1124/mol.116.106617
|
| 26 |
Yan Zhang, Xueyan Gao, Shuochen Gao, Yang Liu, Wenkang Wang, Yudi Feng, Liping Pei, Zhenqiang Sun, Lin Liu, Chengzeng Wang. Effect of gut flora mediated‐bile acid metabolism on intestinal immune microenvironment. Immunology 2023; 170(3): 301 doi: 10.1111/imm.13672
|
| 27 |
Alessia Perino, Hadrien Demagny, Laura Velazquez-Villegas, Kristina Schoonjans. Molecular physiology of bile acid signaling in health, disease, and aging. Physiological Reviews 2021; 101(2): 683 doi: 10.1152/physrev.00049.2019
|
| 28 |
Ahmad Samer Alawad, Cynthia Levy. FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Digestive Diseases and Sciences 2016; 61(12): 3395 doi: 10.1007/s10620-016-4334-8
|
| 29 |
Bing Wang, Haibo Zhang, Zhilin Luan, Hu Xu, Yuanyi Wei, Xuejia Zhao, Miaomiao Xing, Xiaoxiao Huo, Jiayang Zhang, Wen Su, Youfei Guan, Xiaoyan Zhang. Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver. Experimental Cell Research 2020; 390(1): 111949 doi: 10.1016/j.yexcr.2020.111949
|
| 30 |
Stephanie R. Wesolowski, Karim C. El Kasmi, Karen R. Jonscher, Jacob E. Friedman. Developmental origins of NAFLD: a womb with a clue. Nature Reviews Gastroenterology & Hepatology 2017; 14(2): 81 doi: 10.1038/nrgastro.2016.160
|
| 31 |
Hélène Dehondt, Arianna Marino, Laura Butruille, Denis A. Mogilenko, Arielle C. Nzoussi Loubota, Oscar Chávez-Talavera, Emilie Dorchies, Emmanuelle Vallez, Joel Haas, Bruno Derudas, Antonino Bongiovanni, Meryem Tardivel, Folkert Kuipers, Philippe Lefebvre, Sophie Lestavel, Anne Tailleux, David Dombrowicz, Sandrine Caron, Bart Staels. Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis. Molecular Metabolism 2023; 69: 101686 doi: 10.1016/j.molmet.2023.101686
|
| 32 |
Vinod S. Hegade, R. Alexander Speight, Rachel E. Etherington, David E. J. Jones. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therapeutic Advances in Gastroenterology 2016; 9(3): 376 doi: 10.1177/1756283X16630712
|
| 33 |
Zhi Qing Yuan, Ke Wei Li. Role of farnesoid X receptor in cholestasis. Journal of Digestive Diseases 2016; 17(8): 501 doi: 10.1111/1751-2980.12378
|
| 34 |
Ye Eun Cho, Yong Seong Kwon, Seonghwan Hwang. Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease. Liver Research 2023; 7(1): 16 doi: 10.1016/j.livres.2022.06.001
|
| 35 |
Karim C. El Kasmi, Swati Ghosh, Aimee L. Anderson, Michael W. Devereaux, Natarajan Balasubramaniyan, Angelo D’Alessandro, David J. Orlicky, Frederick J. Suchy, Colin T. Shearn, Ronald J. Sokol. Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition–associated cholestasis in mice. Hepatology 2022; 75(2): 252 doi: 10.1002/hep.32101
|
| 36 |
Chao Li, Jie Yang, Yu Wang, Yingzi Qi, Wenqing Yang, Yunlun Li. Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01247
|
| 37 |
Magdalena Rausch, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak-Ublick. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. International Journal of Molecular Sciences 2022; 23(22): 13967 doi: 10.3390/ijms232213967
|
| 38 |
Matthew G. Browning, Bernardo M. Pessoa, Jad Khoraki, Guilherme M. Campos. Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. Current Obesity Reports 2019; 8(2): 175 doi: 10.1007/s13679-019-00334-4
|
| 39 |
Dimitrios S. Karagiannakis, George Papatheodoridis, Jiannis Vlachogiannakos. Recent Advances in Cirrhotic Cardiomyopathy. Digestive Diseases and Sciences 2015; 60(5): 1141 doi: 10.1007/s10620-014-3432-8
|
| 40 |
Jeong Seok Yu, Gi Soo Youn, Jieun Choi, Chang‐Ho Kim, Byung Yong Kim, Seung‐Jo Yang, Je Hee Lee, Tae‐Sik Park, Byoung Kook Kim, Yeon Bee Kim, Seong Woon Roh, Byeong Hyun Min, Hee Jin Park, Sang Jun Yoon, Na Young Lee, Ye Rin Choi, Hyeong Seob Kim, Haripriya Gupta, Hotaik Sung, Sang Hak Han, Ki Tae Suk, Do Yup Lee. Lactobacillus lactis and Pediococcus pentosaceus‐driven reprogramming of gut microbiome and metabolome ameliorates the progression of non‐alcoholic fatty liver disease. Clinical and Translational Medicine 2021; 11(12) doi: 10.1002/ctm2.634
|
| 41 |
Marica Cariello, Elena Piccinin, Oihane Garcia-Irigoyen, Carlo Sabbà, Antonio Moschetta. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018; 1864(4): 1308 doi: 10.1016/j.bbadis.2017.09.019
|
| 42 |
Baoshang Zhou, Bing Feng, Zhexue Qin, Youguang Zhao, Yu Chen, Zhengmin Shi, Yi Gong, Jing Zhang, Fahuan Yuan, Jiao Mu. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. Molecular and Cellular Endocrinology 2016; 419: 72 doi: 10.1016/j.mce.2015.10.001
|
| 43 |
Jianlong Du, Qiang Chen, Yongnan Li, Xiaojun Xiang, Wei Xu, Kangsen Mai, Qinghui Ai. Activation of the Farnesoid X Receptor (FXR) Suppresses Linoleic Acid-Induced Inflammation in the Large Yellow Croaker (Larimichthys crocea). The Journal of Nutrition 2020; 150(9): 2469 doi: 10.1093/jn/nxaa185
|
| 44 |
Anna Bertolini, Romina Fiorotto, Mario Strazzabosco. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Seminars in Immunopathology 2022; 44(4): 547 doi: 10.1007/s00281-022-00935-7
|
| 45 |
Chang Wang, Yitian Yang, Jinyan Chen, Xueyan Dai, Chenghong Xing, Caiying Zhang, Huabin Cao, Xiaoquan Guo, Guoliang Hu, Yu Zhuang. Berberine Protects against High-Energy and Low-Protein Diet-Induced Hepatic Steatosis: Modulation of Gut Microbiota and Bile Acid Metabolism in Laying Hens. International Journal of Molecular Sciences 2023; 24(24): 17304 doi: 10.3390/ijms242417304
|
| 46 |
Ornuma Haonon, Zhigang Liu, Rungtiwa Dangtakot, Porntip Pinlaor, Anucha Puapairoj, Ubon Cha'on, Kitti Intuyod, Thatsanapong Pongking, Chanakan Jantawong, Chatchawan Sengthong, Apisit Chaidee, Sudarat Onsurathum, Jia V. Li, Somchai Pinlaor. Opisthorchis viverrini infection induces metabolic disturbances in hamsters fed with high fat/high fructose diets: Implications for liver and kidney pathologies. The Journal of Nutritional Biochemistry 2022; 107: 109053 doi: 10.1016/j.jnutbio.2022.109053
|
| 47 |
Joscha Vonderlin, Triantafyllos Chavakis, Michael Sieweke, Frank Tacke. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. Cellular and Molecular Gastroenterology and Hepatology 2023; 15(6): 1311 doi: 10.1016/j.jcmgh.2023.03.002
|
| 48 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. Consenso mexicano de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2019; 84(1): 69 doi: 10.1016/j.rgmx.2018.11.007
|
| 49 |
Jiamin Zhang, Chaoyi Wang, Xiawei Ji, Fangquan Wu, Zhebing Lin, Yan Zhou, Changlong Xu, Fangyan Wang, Jian Wu. Bile Acids: A Bridge Linking Gut Microbiota and NAFLD. Advanced Gut & Microbiome Research 2022; 2022: 1 doi: 10.1155/2022/4752148
|
| 50 |
Lijun Luo, Yongchun Chang, Li Sheng. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective. Life Sciences 2023; 321: 121614 doi: 10.1016/j.lfs.2023.121614
|
| 51 |
Aleepta Guha Ray, Oluwatomilayo Patience Odum, Destini Wiseman, Ada Weinstock. The diverse roles of macrophages in metabolic inflammation and its resolution. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1147434
|
| 52 |
Yunlong Xia, Xinyue Xu, Yongzhen Guo, Chen Lin, Xiaoming Xu, Fuyang Zhang, Miaomiao Fan, Tingting Qi, Congye Li, Guangyu Hu, Lu Peng, Shan Wang, Ling Zhang, Chunxu Hai, Rui Liu, Wenjun Yan, Ling Tao. Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile Acids. Advanced Science 2022; 9(24) doi: 10.1002/advs.202200431
|
| 53 |
Brett M. McGettigan, Rachel H. McMahan, Yuhuan Luo, Xiaoxin X. Wang, David J. Orlicky, Cara Porsche, Moshe Levi, Hugo R. Rosen. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. Journal of Biological Chemistry 2016; 291(44): 23058 doi: 10.1074/jbc.M116.731042
|
| 54 |
Hsuan‑Miao Liu, Tzung‑Yan Lee, Jyh‑Fei Liao. GW4064 attenuates lipopolysaccharide‑induced hepatic inflammation and apoptosis through inhibition of the Toll‑like receptor 4‑mediated p38 mitogen‑activated protein kinase signaling pathway in mice. International Journal of Molecular Medicine 2018; doi: 10.3892/ijmm.2018.3366
|
| 55 |
Mariana Verdelho Machado, Anna Mae Diehl. Zakim and Boyer's Hepatology. 2018; : 369 doi: 10.1016/B978-0-323-37591-7.00025-2
|
| 56 |
Valerio Nobili, Anna Alisi, Antonella Mosca, Claudia Della Corte, Silvio Veraldi, Rita De Vito, Cristiano De Stefanis, Valentina D'Oria, Joerg Jahnel, Evelyn Zohrer, Eleonora Scorletti, Christopher D. Byrne. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver International 2018; 38(2): 342 doi: 10.1111/liv.13531
|